Opinion

Video

Adverse Events Associated With TKIs in HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCPMartin Dietrich, MD, PhD

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

Related Videos
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Benjamin Levy, MD
Ibrahim Aldoss, MD
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Tycel Phillips, MD, MPH
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Related Content
Eric Vallieres, MD, FRCSC, of Swedish Medical Center
June 13th 2024

A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center
March 18th 2024

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

Minesh Mehta, MD
June 4th 2024

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

Lung cancer - stock.adobe.com
June 4th 2024

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC